Taysha Gene Therapies Director Sells, Buys Shares Amidst Stock Price Fluctuations

Taysha Gene Therapies, Inc. (TSHA) has announced that Director, President, and Head of Research and Development, Nagendran Sukumar, has executed a transaction involving the sale and purchase of shares. On January 12, 2026, Sukumar sold 200,000 shares at a price of $4.71 per share. In addition, he purchased 88,676 shares at $1.71 per share and 111,324 shares at $0.70 per share on the same date.